Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)
Grant supports partnerships between academia and industry to translate scientific discoveries into tools for disease research and care worldwide.
Funder: National Institutes of Health
Due Dates: June 5, 2025 (New) | July 5, 2025 (Renewal/Resubmission/Revision) | October 5, 2025 (New) | November 5, 2025 (Renewal/Resubmission/Revision) | February 5, 2026 (New) | March 5, 2026 (Renewal/Resubmission/Revision) | June 5, 2026 (New) | July 5, 2026 (Renewal/Resubmission/Revision) | October 5, 2026 (New) | November 5, 2026 (Renewal/Resubmission/Revision) | February 5, 2027 (New) | March 5, 2027 (Renewal/Resubmission/Revision) | June 5, 2027 (New) | July 5, 2027 (Renewal/Resubmission/Revision) | October 5, 2027 (New) | November 5, 2027 (Renewal/Resubmission/Revision)
Funding Amounts: Up to $499,000 direct costs per year, for up to 5 years (R01 mechanism).
Summary: Supports academic-industry partnerships to translate scientific and engineering advances into technologies or tools for disease research, diagnosis, and treatment, with a focus on cancer and related conditions.
Key Information: Requires at least one academic and one industrial partner; clinical trials are optional but must be translational in focus; phase III trials and commercial production are not supported.
Description
This funding opportunity from the National Cancer Institute (NCI) at the NIH is designed to accelerate the translation of scientific discoveries and engineering developments into practical technologies, methods, or tools that address key problems in disease research, risk assessment, detection, diagnosis, treatment, and management. The program specifically supports interdisciplinary, multi-institutional partnerships between academic and industrial organizations, aiming to bridge gaps in expertise and facilitate the development and validation of solutions that are ready for end-user adoption in pre-clinical, clinical, or non-clinical settings.
The initiative emphasizes innovation defined as the likelihood to deliver a new capability to end users, and encourages projects that address affordability, reproducibility, quality assurance, and applicability in low-resource or underserved settings. While clinical trials are allowed (and may be included to validate new technologies), the primary focus must be on translation rather than late-stage (phase III) clinical testing or commercial production.
